Venus Remedies Limited (NSE:VENUSREM)

India flag India · Delayed Price · Currency is INR
437.00
-10.80 (-2.41%)
Jun 5, 2025, 3:29 PM IST
38.14%
Market Cap 5.98B
Revenue (ttm) 6.48B
Net Income (ttm) 453.20M
Shares Out n/a
EPS (ttm) 33.90
PE Ratio 13.20
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 39,613
Average Volume 153,939
Open 447.80
Previous Close 447.80
Day's Range 427.20 - 448.00
52-Week Range 270.25 - 476.90
Beta 0.62
RSI 78.33
Earnings Date May 30, 2025

About Venus Remedies

Venus Remedies Limited engages in the pharmaceutical business in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones, immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, solvent, respiratory, and anticoagulant. It is also involved in the provision of portfolio of herbal products. Venus Remedies Limi... [Read more]

Sector Healthcare
Founded 1989
Employees 1,187
Stock Exchange National Stock Exchange of India
Ticker Symbol VENUSREM
Full Company Profile

Financial Performance

In 2024, Venus Remedies's revenue was 6.48 billion, an increase of 7.72% compared to the previous year's 6.01 billion. Earnings were 453.20 million, an increase of 59.07%.

Financial Statements

News

Venus Remedies renews GMP certification from Ukraine’s SMDC for Baddi facility

Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a pharmaceutical manufacturer headquartered in India, has renewed its Good Manufacturing Practices (GMP) certification from the State Service of Uk...

14 days ago - Business Upturn

Venus Remedies shares jump 11% after US FDA grants QIDP status to novel antibiotic VRP-034

Shares of Venus Remedies surged over 11% in Wednesday’s trade, climbing to ₹347.65 on the NSE, after the company announced that its novel antibiotic formulation VRP-034 has received Qualified Infectio...

7 weeks ago - Business Upturn

Venus Remedies gets US FDA grants QIDP status to novel polymyxin B formulation VRP-034

Venus Remedies Limited has received a significant regulatory boost with the United States Food and Drug Administration (US FDA) granting Qualified Infectious Disease Product (QIDP) designation to its ...

7 weeks ago - Business Upturn

Venus Remedies secures exclusive rights for MET-X clinical development in India

Venus Remedies Ltd, a renowned Indian pharmaceutical company specializing in antimicrobial resistance (AMR), has entered into an exclusive licensing agreement with UK-based Infex Therapeutics. This co...

3 months ago - Business Upturn

Venus Remedies shares surge 10% after EU GMP Certification renewal

Venus Remedies saw its shares jumped 10% after securing the renewal of its European Good Manufacturing Practices (EU GMP) certification from Infarmed, Portugal’s National Authority of Medicines and He...

4 months ago - Business Upturn

Venus Remedies successfully renews EU GMP certification, reinforcing its European market presence

Venus Remedies Limited has announced the successful renewal of its European Good Manufacturing Practices (EU GMP) certification. Granted by Infarmed, the National Authority of Medicines and Health Pro...

4 months ago - Business Upturn

Venus Remedies stock jumps 4% after receiving GMP certification for Antibiotic facility

Shares of Venus Remedies surged 4% after the company received a Good Manufacturing Practice (GMP) certification from the Ministry of Health of Moldova for its carbapenem antibiotic facility. This cert...

5 months ago - Business Upturn

Venus Remedies shares surge 6% on Pemetrexed marketing authorization in Philippines

Venus Remedies’ stock jumped 6% following the announcement of marketing authorization for Pemetrexed 500mg, a chemotherapy agent used to treat lung cancer and mesothelioma, in the Philippines. This ap...

6 months ago - Business Upturn